785 related articles for article (PubMed ID: 33104034)
21. The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey.
Bocchetta M; Galluzzi S; Kehoe PG; Aguera E; Bernabei R; Bullock R; Ceccaldi M; Dartigues JF; de Mendonça A; Didic M; Eriksdotter M; Félician O; Frölich L; Gertz HJ; Hallikainen M; Hasselbalch SG; Hausner L; Heuser I; Jessen F; Jones RW; Kurz A; Lawlor B; Lleo A; Martinez-Lage P; Mecocci P; Mehrabian S; Monsch A; Nobili F; Nordberg A; Rikkert MO; Orgogozo JM; Pasquier F; Peters O; Salmon E; Sánchez-Castellano C; Santana I; Sarazin M; Traykov L; Tsolaki M; Visser PJ; Wallin ÅK; Wilcock G; Wilkinson D; Wolf H; Yener G; Zekry D; Frisoni GB
Alzheimers Dement; 2015 Feb; 11(2):195-206.e1. PubMed ID: 25150733
[TBL] [Abstract][Full Text] [Related]
22. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
[TBL] [Abstract][Full Text] [Related]
23. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
24. Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment.
Herukka SK; Simonsen AH; Andreasen N; Baldeiras I; Bjerke M; Blennow K; Engelborghs S; Frisoni GB; Gabryelewicz T; Galluzzi S; Handels R; Kramberger MG; Kulczyńska A; Molinuevo JL; Mroczko B; Nordberg A; Oliveira CR; Otto M; Rinne JO; Rot U; Saka E; Soininen H; Struyfs H; Suardi S; Visser PJ; Winblad B; Zetterberg H; Waldemar G
Alzheimers Dement; 2017 Mar; 13(3):285-295. PubMed ID: 28341066
[TBL] [Abstract][Full Text] [Related]
25. Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI.
Wolfsgruber S; Jessen F; Koppara A; Kleineidam L; Schmidtke K; Frölich L; Kurz A; Schulz S; Hampel H; Heuser I; Peters O; Reischies FM; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Pantel J; Rienhoff O; Rüther E; Henn F; Wiltfang J; Maier W; Kornhuber J; Wagner M
Neurology; 2015 Mar; 84(12):1261-8. PubMed ID: 25716354
[TBL] [Abstract][Full Text] [Related]
26. Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis.
Michaud TL; Kane RL; McCarten JR; Gaugler JE; Nyman JA; Kuntz KM;
J Alzheimers Dis; 2015; 47(3):729-40. PubMed ID: 26401707
[TBL] [Abstract][Full Text] [Related]
27. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
[TBL] [Abstract][Full Text] [Related]
28. Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study.
Miebach L; Wolfsgruber S; Polcher A; Peters O; Menne F; Luther K; Incesoy E; Priller J; Spruth E; Altenstein S; Buerger K; Catak C; Janowitz D; Perneczky R; Utecht J; Laske C; Buchmann M; Schneider A; Fliessbach K; Kalbhen P; Heneka MT; Brosseron F; Spottke A; Roy N; Teipel SJ; Kilimann I; Wiltfang J; Bartels C; Düzel E; Dobisch L; Metzger C; Meiberth D; Ramirez A; Jessen F; Wagner M
Alzheimers Res Ther; 2019 Jul; 11(1):66. PubMed ID: 31366409
[TBL] [Abstract][Full Text] [Related]
29. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.
van Maurik IS; Zwan MD; Tijms BM; Bouwman FH; Teunissen CE; Scheltens P; Wattjes MP; Barkhof F; Berkhof J; van der Flier WM;
JAMA Neurol; 2017 Dec; 74(12):1481-1491. PubMed ID: 29049480
[TBL] [Abstract][Full Text] [Related]
30. White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
van Waalwijk van Doorn LJC; Ghafoorian M; van Leijsen EMC; Claassen JAHR; Arighi A; Bozzali M; Cannas J; Cavedo E; Eusebi P; Farotti L; Fenoglio C; Fortea J; Frisoni GB; Galimberti D; Greco V; Herukka SK; Liu Y; Lleó A; de Mendonça A; Nobili FM; Parnetti L; Picco A; Pikkarainen M; Salvadori N; Scarpini E; Soininen H; Tarducci R; Urbani A; Vilaplana E; Meulenbroek O; Platel B; Verbeek MM; Kuiperij HB
J Alzheimers Dis; 2021; 79(1):163-175. PubMed ID: 33252070
[TBL] [Abstract][Full Text] [Related]
31. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
32. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
Podhorna J; Krahnke T; Shear M; Harrison JE;
Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
[TBL] [Abstract][Full Text] [Related]
33. Intrinsic functional connectivity, CSF biomarker profiles and their relation to cognitive function in mild cognitive impairment.
Matura S; Köhler J; Reif A; Fusser F; Karakaya T; Scheibe M; Ehret F; Hartmann D; Kang JS; Mayer C; Prvulovic D; Pantel J
Acta Neuropsychiatr; 2020 Aug; 32(4):206-213. PubMed ID: 31801648
[TBL] [Abstract][Full Text] [Related]
34. Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum.
Paciotti S; Wojdała AL; Bellomo G; Toja A; Chipi E; Piersma SR; Pham TV; Gaetani L; Jimenez CR; Parnetti L; Chiasserini D
Alzheimers Res Ther; 2023 Jul; 15(1):124. PubMed ID: 37454217
[TBL] [Abstract][Full Text] [Related]
35. Association of Subjective Cognitive Decline with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
Wen C; Bi YL; Hu H; Huang SY; Ma YH; Hu HY; Tan L; Yu JT
J Alzheimers Dis; 2022; 85(3):1143-1151. PubMed ID: 34924386
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.
Niemantsverdriet E; Goossens J; Struyfs H; Martin JJ; Goeman J; De Deyn PP; Vanderstichele H; Engelborghs S
J Alzheimers Dis; 2016; 51(1):97-106. PubMed ID: 26836187
[TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal fluid biomarkers and prediction of conversion in patients with mild cognitive impairment: 4-year follow-up in a routine clinical setting.
Lanari A; Parnetti L
ScientificWorldJournal; 2009 Sep; 9():961-6. PubMed ID: 19768352
[TBL] [Abstract][Full Text] [Related]
38. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
[TBL] [Abstract][Full Text] [Related]
39. Clinical Utility of Cerebrospinal Fluid Aβ42 and Tau Measures in Diagnosing Mild Cognitive Impairment in Early Onset Dementia.
Hosseini AA; Brown T; Mannino L; Gran B; Junaid K; Mukaetova-Ladinska EB
J Alzheimers Dis; 2022; 87(2):771-780. PubMed ID: 35404281
[TBL] [Abstract][Full Text] [Related]
40. Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia.
Naudé PJW; Ramakers IHGB; van der Flier WM; Jiskoot LC; Reesink FE; Claassen JAHR; Koek HL; Eisel ULM; De Deyn PP
Neurobiol Aging; 2021 Nov; 107():1-10. PubMed ID: 34365256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
